Literature DB >> 2936301

Comprehensive evaluation of ciprofloxacin-aminoglycoside combinations against Enterobacteriaceae and Pseudomonas aeruginosa strains.

I Haller.   

Abstract

The in vitro activities of antibiotic combinations containing ciprofloxacin and either gentamicin, sisomicin, netilmicin, amikacin, or tobramycin were evaluated by checkerboard assay (agar dilution method). A total of 220 strains of Enterobacteriaceae and Pseudomonas aeruginosa (11 species, 20 strains each) were tested. Synergistic or antagonistic effects were observed in less than 1% of the tests performed; they appeared to represent method-dependent fluctuations rather than true antibiotic interactions. No significant differences among the five aminoglycosides tested were seen. Time-kill experiments performed with three representative strains of Escherichia coli and Serratia marcescens showed additive combination effects with respect to the kill rates and inhibition of bacterial regrowth. Exposure of Serratia strains to either ciprofloxacin or gentamicin before the addition of the second drug had little influence on the combination effects observed. No antagonistic drug interactions were seen in vivo when combination therapy with ciprofloxacin and gentamicin was evaluated in a model of E. coli thigh muscle infection in neutropenic mice. Comparable therapeutic effects were obtained, regardless of whether the two compounds were administered simultaneously or sequentially at 1- or 2-h intervals.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2936301      PMCID: PMC176353          DOI: 10.1128/AAC.28.5.663

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites.

Authors:  G B ELION; S SINGER; G H HITCHINGS
Journal:  J Biol Chem       Date:  1954-06       Impact factor: 5.157

2.  Interaction between ciprofloxacin and tobramycin or azlocillin against multiresistant strains of Acinetobacter anitratum in vitro.

Authors:  B P Overbeek; M Rozenberg-Arska; J Verhoef
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 3.267

3.  Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method.

Authors:  H O Hallander; K Dornbusch; L Gezelius; K Jacobson; I Karlsson
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

4.  Effect of temocillin in combination with other beta-lactam antibiotics.

Authors:  L Verbist; J Verhaegen
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

5.  Comparison of azlocillin, ceftizoxime, cefoxitin, and amikacin alone and in combination against Pseudomonas aeruginosa in a neutropenic-site rabbit model.

Authors:  L R Peterson; D N Gerding; J A Moody; C E Fasching
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

6.  Imipenem antagonism of the in vitro activity of piperacillin against Pseudomonas aeruginosa.

Authors:  M A Bertram; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

7.  The in vitro and in vivo activity of ciprofloxacin.

Authors:  H J Zeiler; K Grohe
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

8.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

9.  In vitro activity of ciprofloxacin against aerobic gram-negative bacteria.

Authors:  J E Rudin; C W Norden; E M Shinners
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

  9 in total
  21 in total

Review 1.  In vivo antibiotic synergism: contribution of animal models.

Authors:  B Fantin; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

Review 2.  Synergy and antagonism of combinations with quinolones.

Authors:  H C Neu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

3.  In vitro activity of aztreonam, cefotaxime, ceftazidime and imipenem combined with ciprofloxacin against gram-negative bacilli and compared with amikacin combinations against Pseudomonas aeruginosa.

Authors:  M Díez Enciso
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

4.  Clinical uses of nalidixic acid analogues: the fluoroquinolones.

Authors:  N Høiby
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

5.  Attenuation of gentamicin-induced nephrotoxicity in rats by fleroxacin.

Authors:  D Beauchamp; G Laurent; L Grenier; P Gourde; J Zanen; J A Heuson-Stiennon; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

6.  Synergistic interactions of ciprofloxacin and extended-spectrum beta-lactams or aminoglycosides against multiply drug-resistant Pseudomonas maltophilia.

Authors:  A W Chow; J Wong; K H Bartlett
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

7.  In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin.

Authors:  D Milatovic; C Wallrauch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-08       Impact factor: 3.267

8.  Ciprofloxacin interactions with imipenem and amikacin against multiresistant Pseudomonas aeruginosa.

Authors:  H Giamarellou; G Petrikkos
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

Review 9.  Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents.

Authors:  H C Neu
Journal:  Drugs       Date:  1993       Impact factor: 9.546

10.  Interactions of ciprofloxacin with clindamycin, metronidazole, cefoxitin, cefotaxime, and mezlocillin against gram-positive and gram-negative anaerobic bacteria.

Authors:  J L Whiting; N Cheng; A W Chow
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.